(CercleFinance.com) – AB Science announces this evening that it has received authorization from the Swedish Health Agency to initiate a Phase III study evaluating masitinib in patients with primary progressive multiple sclerosis (PPMS) or multiple sclerosis. non-active secondary progressive plaques (nSPMS).
‘This authorization represents a key step not only for the clinical program of masitinib in the progressive forms of multiple sclerosis, but also for the entire clinical program of masitinib in neurology’, reacted Pr Olivier Hermine, chairman of the committee. AB Science scientist and member of the Academy of Sciences.
AB Science states that to date, masitinib has obtained positive phase 2B/3 results in three neurodegenerative diseases, namely Alzheimer’s disease, amyotrophic lateral sclerosis, and progressive forms of multiple sclerosis.
“We are committed to continuing the clinical development program of masitinib in each of these very challenging neurological diseases, with the ultimate goal of improving the lives of patients,” added the professor.